Get started
Author

Sandra S. Hammer

Observed names: Hammer, Sandra, S. S. Hammer, Sandra Hammer, Sandra Suarez Hammer
ORCID: 0009-0003-7760-4582
Observed ORCID: 0009-0003-7760-4582
OpenAlex ID: A5113415695
Comparative analysis of Endoxifen, Tamoxifen and Fulvestrant: A Bioinformatics Approach to Uncover Mechanisms of Action in Breast Cancer
2024 · H. Lawrence Remmel, Sandra S. Hammer, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 6
PDF
A Hypothesized Therapeutic Role of (Z)-Endoxifen in Duchenne Muscular Dystrophy (DMD)
2025 · H Lawrence Remmel, Sandra Hammer, et al. · Degenerative Neurological and Neuromuscular Disease · 1
PDF
Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity in ERα+ breast cancer
2026 · Lena Batoon, Rajeev S. Muthyala, et al. · npj Breast Cancer
Abstract A010: Dual estrogen receptor and PKCβ signaling modulation by (Z)-Endoxifen: A mechanism-driven therapeutic strategy for estrogen-driven pathology in McCune–Albright Syndrome
2026 · Sandra S. Hammer, Janet R. Rea, et al. · Cancer Research
BH3 mimetics as single agents and with endoxifen in ERα+ breast cancer models
2026 · Lena Batoon, Xiyin Wang, et al. · Research Square
PDF
Abstract 1784: Mechanistic characterization of (Z)-endoxifen in ESR1-mutant and endocrine-resistant breast cancer
2026 · Sandra Suarez Hammer, Alina Ustiugova, et al. · Cancer Research
Abstract 405: (Z)-endoxifen modulates estrogen receptor and cell-cycle signaling to induce synergistic antiproliferative effects with CDK4/6 inhibition in endometrial cancer models.
2026 · Grace Choong, Xiaonan Hou, et al. · Cancer Research
PCO26-270: Transcriptomic Profiling Reveals Inflammatory and Epithelial-Mesenchymal Transition Pathway Activation in Endoxifen-Resistant Estrogen Receptor–Positive Breast Cancer
2026 · H. Lawrence Remmel, Sandra Hammer, et al. · Journal of the National Comprehensive Cancer Network
Abstract PD10-05: (z)-endoxifen maintains erα antagonist function against esr1 mutants via inactive conformation stabilization and reversal of mutant esr1-associated transcriptional signatures
2026 · S. S. Hammer, E. Kirilin, et al. · Clinical Cancer Research
Abstract PS5-12-16: A Phase 2 Trial of (Z)-endoxifen + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+, HER2-, Breast Cancer (EVANGELINE)
2026 · M. P. Goetz, V. J. Suman, et al. · Clinical Cancer Research
(Z)-Endoxifen as a Modulator of Utrophin Pathways in Duchenne Muscular Dystrophy: A Mechanistic and Transcriptomic Perspective
2026 · Remmel, H. Lawrence, Hammer, Sandra, et al. · Zenodo (CERN European Organization for Nuclear Research)
Evaluation of (Z)-endoxifen as a potential therapy for glioblastoma multiforme through computational and experimental analyses
2025 · Anastasia Shneyderman, Sandra S. Hammer, et al. · Scientific Reports
PDF
Abstract P2-12-18: A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+/HER2-Breast Cancer (EVANGELINE)
2025 · Matthew Goetz, Vera J. Suman, et al. · Clinical Cancer Research
Abstract P4-05-22: Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer
2025 · Daniela Hühn, Maria Häggblad, et al. · Clinical Cancer Research
Abstract CT237: A randomized phase 2 non-inferiority trial of (Z)-endoxifen + goserelin and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE)
2025 · Matthew P. Goetz, Vera J. Suman, et al. · Cancer Research
Abstract CT257: SMART 2.0 Interval breast cancer reduction study: A phase 3 randomized, double-blind, placebo-controlled trial of oral Z-endoxifen in women at high risk for breast cancer
2025 · Steven C. Quay, H. Lawrence Remmel, et al. · Cancer Research
Abstract 4742: Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity in ERα+ breast cancer
2025 · Lena Batoon, Rajeev S. Muthyala, et al. · Cancer Research
Uncovering the transcriptomic basis of endoxifen resistance in ER+ breast cancer cells: Insights from bioinformatics analysis
2025 · H. Lawrence Remmel, Sandra S. Hammer, et al. · Cancer Treatment and Research Communications
Abstract A007: Anti-cancer activity of (Z)-endoxifen-related compounds in ERα+ breast cancer
2024 · Natalie Farris, Lena Batoon, et al. · Molecular Cancer Therapeutics
Works count: 19
Citation count: 7
H-index: 1
I10-index:
Year
Topic
Type